As for CD8+ T cells, not only did their relative number dramatically increase, but also the relative number of tumor-specific T cells, as determined by TRP-2 pentamer-binding by tumor infiltrating lymphocytes (TILs), showed about 12-fold and a 7-fold increase in CXCL9-Fc and CXCL10-Fc treated mice, respectively (Figure 5C, a). This evidence concerns the gene CXCL9 and neoplasm.